UK blood cancer 5-year survival is now around 70 percent overall and rising faster than survival for many other common cancers – subtype, age and access to newer therapies like CAR-T are the biggest drivers of individual outcomes.

Blood Cancer Survival Rate UK 2026: NHS Figures by Type for Lymphoma, Leukaemia and Myeloma

You or someone you love has just been told they have blood cancer. The words – leukaemia, lymphoma, myeloma – are still hanging in the air when you reach for your phone. You type “blood cancer survival rate” into a search engine and the numbers feel overwhelming, contradictory and frightening.

Take a breath. This guide is written in the calm, measured voice of a GP consultation. It is anchored to UK 2026 evidence and aimed at patients, families and carers who want honest, clear information without sensationalism.

We will walk through what blood cancers actually are and what survival rates do and do not mean. We will look at the UK figures by main type – leukaemia broken down by subtype, lymphoma by Hodgkin and non-Hodgkin, and myeloma. We will explain why survival has improved so much over the past decade, what changes the numbers for an individual patient, and what the NHS pathway looks like in 2026.

This article covers the basics of blood cancer, what survival rates really mean, the figures by type, the reasons for improvement, individual factors and the NHS pathway.

What Blood Cancer Is and What Survival Rate Actually Means

Blood cancers – sometimes called haematological malignancies – are a family of cancers that start in the cells of the blood and bone marrow. The three main groups are leukaemia, a cancer of white blood cells; lymphoma, a cancer of lymphocytes in the lymphatic system; and myeloma, a cancer of plasma cells in the bone marrow. There are also rarer types including myelodysplastic syndromes and myeloproliferative neoplasms.

Around 40,000 people are diagnosed with a blood cancer each year in the UK, and there are roughly 250,000 people living with blood cancer at any one time. It is the fifth most common cancer group in the country.

The most important thing to understand about any “survival rate” is that it is a population statistic. It describes how groups of patients diagnosed in a recent five-year window fared on average. It is not a prediction about what will happen to you or to someone you care about.

Many factors change individual survival: the exact subtype of blood cancer, the patient’s age and general fitness, the genetic features of the cancer, how well it responds to first-line treatment, and whether the patient has access to newer therapies and clinical trials. Many UK blood cancer patients live well beyond the headline statistics quoted in this article.

The numbers are also improving year on year. Today’s published five-year survival figures reflect treatment given several years ago. Anyone diagnosed in 2026 is starting treatment in a more favourable era than those numbers suggest. The overall UK five-year relative survival for blood cancer is now around 70 percent according to Blood Cancer UK, and blood cancer survival is rising faster than survival for many other common cancers.

Leukaemia Survival Rates UK 2026 – By Subtype

Leukaemia is not one cancer. There are four main subtypes plus rarer forms, and the outcomes vary enormously between them.

Acute lymphoblastic leukaemia (ALL) has an overall 5-year survival of around 70 percent in the UK. In children, the figure is over 90 percent – ALL is one of the great success stories of paediatric oncology. In older adults, survival is lower, which pulls the overall average down.

Acute myeloid leukaemia (AML) has the lowest 5-year survival of the common blood cancers at around 22 percent overall. This figure needs careful interpretation. Around 41 percent of new UK AML cases are diagnosed in people aged 75 and older, and older patients are far less likely to be fit enough for intensive chemotherapy. Younger fit adults with AML can achieve 50 percent or higher 5-year survival, particularly when the cancer carries favourable genetic mutations.

Chronic lymphocytic leukaemia (CLL) has 5-year survival over 80 percent. Many patients live for years, sometimes a decade or more, on watch-and-wait before any treatment is needed. When treatment is required, targeted drugs like ibrutinib, acalabrutinib and venetoclax have transformed outcomes.

Chronic myeloid leukaemia (CML) also has 5-year survival over 80 percent. The drug imatinib, sold as Glivec, introduced in the early 2000s, and newer tyrosine kinase inhibitors, mean many CML patients now have a near-normal life expectancy.

Overall leukaemia 5-year survival in the UK has risen from around 45.8 percent to around 52.5 percent across recent five-year data windows. About 49 percent of UK leukaemia patients survive 10 years or more.

Lymphoma Survival Rates UK 2026 – Hodgkin and Non-Hodgkin

Lymphoma is broadly split into two types: Hodgkin lymphoma and non-Hodgkin lymphoma. The distinction matters because the treatments, biology and survival figures are quite different.

Hodgkin lymphoma is less common but has a particularly high cure rate. Around 80 percent of UK Hodgkin lymphoma patients survive 5 years, and over 75 percent survive 10 years. Young patients with early-stage Hodgkin lymphoma have cure rates above 90 percent. Modern combination chemotherapy regimens and, for some patients, immunotherapy with checkpoint inhibitors such as nivolumab and pembrolizumab, have driven survival to historic highs.

Non-Hodgkin lymphoma is more common and is itself a family of around 60 subtypes with very different outlooks. Overall 5-year survival for non-Hodgkin lymphoma in England is around 65 percent according to Cancer Research UK data covering 2016 to 2020. Ten-year survival is predicted to be around 64.6 percent.

Within the non-Hodgkin lymphoma family, follicular lymphoma has over 80 percent 5-year survival and many patients live for decades. Diffuse large B-cell lymphoma, the most common subtype, has around 65 percent 5-year survival, and many of those who reach remission are cured. Mantle cell lymphoma has historically had around 57 percent 5-year survival, though newer targeted treatments are improving these numbers.

Non-Hodgkin lymphoma survival in the UK has improved enormously since the 1970s, when 10-year survival was about 22.8 percent. The improvement is driven by rituximab and other monoclonal antibodies, targeted drugs like ibrutinib, and most recently CAR-T cell therapy.

Faster NHS diagnostic pathways and molecular testing mean blood cancer patients reach specialist care more quickly than ever before.

Myeloma Survival Rate UK 2026 – The Fastest-Improving Blood Cancer

Myeloma is a cancer of plasma cells in the bone marrow and was historically one of the harder blood cancers to treat. That picture is changing fast.

UK myeloma 5-year survival has risen from around 42.5 percent for patients diagnosed between 2006 and 2010 to around 51.7 percent for those diagnosed between 2012 and 2016. That is a 9 percentage point gain in just six years. In 2026, UK myeloma 5-year survival is generally quoted around 55 to 62 percent depending on the data source.

Several drug classes have driven this improvement. Proteasome inhibitors such as bortezomib and carfilzomib attack a mechanism myeloma cells depend on. Immunomodulatory drugs including lenalidomide and pomalidomide reshape the immune response against the cancer. The monoclonal antibody daratumumab has become a standard part of many treatment regimens. Increasing use of stem cell transplant has helped too, particularly as reduced-intensity conditioning has made transplant an option for more patients.

The newest leap forward is CAR-T cell therapy. Two CAR-T treatments – ciltacabtagene autoleucel and idecabtagene vicleucel – are now NHS-funded for some patients with relapsed and refractory myeloma. Recent trial data shows around 1 in 3 patients still in remission five years after a single CAR-T infusion. The MajesTEC-3 trial of teclistamab plus daratumumab achieved an overall response rate of 89.5 percent in relapsed disease. These newer therapies are often better tolerated than older chemotherapy regimens, so quality of life during treatment has also improved.

Myeloma is now considered a treatable long-term condition for many patients rather than a quickly terminal illness. Patients newly diagnosed in 2026 are starting treatment in a much more favourable era than the historical statistics suggest, and outcomes are likely to be better still by the time the next data window is published.

Why Blood Cancer Survival Has Improved So Much

Six major drivers explain the leap in UK blood cancer survival over the past decade.

First, targeted therapies. These are drugs that hit specific molecules cancer cells need to survive, often with fewer side effects than traditional chemotherapy. Imatinib for CML, ibrutinib for CLL and mantle cell lymphoma, venetoclax for CLL and AML – each has reshaped the outlook for its respective disease.

Second, monoclonal antibodies. Rituximab transformed treatment for non-Hodgkin lymphoma and CLL from the early 2000s. Daratumumab has reshaped myeloma care. These laboratory-made proteins home in on markers on the surface of cancer cells.

Third, CAR-T cell therapy. A patient’s own T cells are collected, genetically modified to recognise and kill blood cancer cells, and infused back into the body. CAR-T is now NHS-funded for some adult lymphomas, paediatric ALL and relapsed myeloma. It can produce durable remissions even in patients whose disease did not respond to earlier treatments.

Fourth, stem cell transplant. Safer techniques and reduced-intensity conditioning regimens have widened the pool of patients who can benefit, including more older adults.

Fifth, faster and more precise diagnosis. The NHS 28-day faster diagnosis standard, rapid diagnostic centres, and molecular and genetic testing of cancer biopsies mean patients reach specialist care quickly and with subtype-level precision. Treatment is matched to the biology of the individual cancer.

Sixth, better supportive care. Growth factors, prophylactic antibiotics and antifungals, and improved transfusion practice all reduce the risks of intensive treatment, meaning patients can tolerate more effective regimens.

Together, these improvements mean a UK patient diagnosed with blood cancer in 2026 is in a substantially better position than one diagnosed even a decade ago. The published five-year survival figures reflect treatment given several years ago, so the real outcomes for today’s patients are likely to be better still.

What Changes Individual Survival, and the NHS Pathway in 2026

Many things influence how an individual patient does. Exact subtype is one of the most powerful – the variation within “lymphoma” or “leukaemia” is enormous, as the figures above show. Age and general fitness matter: older patients with fewer co-existing illnesses tend to do better than those managing multiple medical problems. Genetic features of the cancer itself are increasingly important, as some mutations respond very well to targeted drugs while others remain harder to treat. Stage at diagnosis plays a role, though “stage” means something different in blood cancers than in solid tumours. Response to first-line treatment is a strong signal: a complete remission after the first course of therapy is one of the most positive signs a haematologist can see. Access to clinical trials and specialist haematology centres also affects outcomes, and UK patients benefit from a strong trial infrastructure.

The NHS pathway in 2026 works as follows. Your GP suspects blood cancer based on red flags such as unexplained persistent fatigue, weight loss, persistent lymph node swelling, easy bruising or bleeding, recurrent infections, unexplained bone pain, drenching night sweats or persistent itch without rash. The GP arranges blood tests including a full blood count and blood film. If the results raise concern, the GP makes an urgent two-week suspected cancer referral to haematology. Specialist assessment may include a bone marrow biopsy, lymph node biopsy and imaging. The diagnosis and treatment plan are discussed at a multidisciplinary team meeting. Treatment options may include watch-and-wait, chemotherapy, targeted therapy, immunotherapy, stem cell transplant, CAR-T cell therapy or clinical trial enrolment. Follow-up is years to lifelong depending on subtype.

One important note: a 2026 BJC Reports study found that UK patients in the most deprived areas have worse survival than those in the least deprived. For non-Hodgkin lymphoma, 5-year survival was 59.2 percent in the most deprived group compared with 69.1 percent in the least deprived. This reflects later diagnosis, more co-existing illnesses and unequal access to trials. Earlier presentation and equitable access to treatment remain national priorities.

Frequently Asked Questions

What is the overall blood cancer survival rate in the UK in 2026?

The overall UK 5-year relative survival rate for blood cancer is around 70 percent according to Blood Cancer UK. This figure averages all blood cancer types and hides huge variation between subtypes. Chronic myeloid leukaemia, chronic lymphocytic leukaemia and follicular lymphoma have 5-year survival over 80 percent. Acute myeloid leukaemia is around 22 percent overall. Hodgkin lymphoma is around 80 percent. Non-Hodgkin lymphoma is around 65 percent. Myeloma is around 55 to 62 percent. Subtype, age and treatment response matter more than the headline number.

What is the survival rate for non-Hodgkin lymphoma in the UK?

Around 65 percent of UK non-Hodgkin lymphoma patients survive 5 years, based on Cancer Research UK data for England covering 2016 to 2020. Around 64.6 percent are predicted to survive 10 years. Within non-Hodgkin lymphoma, outcomes vary by subtype: follicular lymphoma has over 80 percent 5-year survival, diffuse large B-cell lymphoma around 65 percent, and mantle cell lymphoma around 57 percent. Newer treatments including rituximab, ibrutinib and CAR-T cell therapy have substantially improved outcomes. Survival has risen from about 22.8 percent 10-year survival in the 1970s.

How long can you live with chronic lymphocytic leukaemia?

Five-year survival for chronic lymphocytic leukaemia is over 80 percent in the UK, and many patients live for many years – often a decade or more beyond diagnosis. CLL is one of the indolent, slow-growing blood cancers and is sometimes managed on watch-and-wait for years before treatment is needed. When treatment is required, targeted drugs like ibrutinib, acalabrutinib and venetoclax have transformed outcomes. Many older UK CLL patients live a near-normal lifespan. Your haematologist can give a personalised prognosis based on the specific features of your disease.

Has myeloma survival really improved that much?

Yes. Myeloma has been one of the fastest-improving blood cancers. UK 5-year survival has risen from around 42.5 percent for patients diagnosed between 2006 and 2010 to around 51.7 percent for those diagnosed between 2012 and 2016, and is generally quoted around 55 to 62 percent in 2026. The drivers are proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies like daratumumab, increasing use of stem cell transplant, and now CAR-T cell therapy. CAR-T trials show around 1 in 3 patients still in remission 5 years after a single infusion. Myeloma is now treatable long-term for many patients.

Why is acute myeloid leukaemia survival so much lower?

AML survival in the UK is around 22 percent overall at 5 years – much lower than many other blood cancers – largely because AML is most often diagnosed in older patients. Around 41 percent of new UK AML cases are in people aged 75 and over, and older patients tend to have more co-existing illnesses that limit intensive treatment. Younger fit adults with AML can have 50 percent or higher 5-year survival, particularly with favourable genetic features. Newer targeted drugs like venetoclax are improving outcomes for older patients too.

What symptoms should make me see the GP about possible blood cancer?

See your GP if you have persistent fatigue not improving with rest, unexplained weight loss, a lymph node swelling in the neck, armpit or groin that does not go away within 2 to 3 weeks, easy bruising or bleeding, recurrent infections, unexplained bone pain, drenching night sweats, or persistent itch without a rash. Most of these symptoms have benign causes. The GP will check with a full blood count blood test and refer to haematology if the results raise concern. Early diagnosis improves outcomes.

This article is informational only and does not replace personalised advice from your GP, pharmacist, or another qualified healthcare professional.